Taro Pharmaceutical Industries Ltd.
TARO · NYSE
3/31/2024 | 3/31/2023 | 3/31/2022 | 3/31/2021 | |
|---|---|---|---|---|
| Revenue | $629 | $573 | $561 | $549 |
| % Growth | 9.8% | 2.1% | 2.3% | – |
| Cost of Goods Sold | $324 | $305 | $268 | $252 |
| Gross Profit | $305 | $268 | $293 | $297 |
| % Margin | 48.5% | 46.8% | 52.2% | 54% |
| R&D Expenses | $65 | $52 | $55 | $60 |
| G&A Expenses | $0 | $85 | $57 | $53 |
| SG&A Expenses | $219 | $198 | $114 | $91 |
| Sales & Mktg Exp. | $0 | $113 | $57 | $39 |
| Other Operating Expenses | $0 | $2 | $0 | $0 |
| Operating Expenses | $283 | $251 | $168 | $152 |
| Operating Income | $22 | $18 | $184 | $704 |
| % Margin | 3.4% | 3.1% | 32.8% | 128.3% |
| Other Income/Exp. Net | $75 | $20 | -$47 | -$536 |
| Pre-Tax Income | $83 | $38 | $78 | -$391 |
| Tax Expense | $29 | $13 | $20 | $10 |
| Net Income | $54 | $25 | $58 | -$401 |
| % Margin | 8.6% | 4.4% | 10.4% | -73% |
| EPS | 1.43 | 0.68 | 1.55 | -10.49 |
| % Growth | 110.3% | -56.1% | 114.8% | – |
| EPS Diluted | 1.43 | 0.68 | 1.55 | -10.49 |
| Weighted Avg Shares Out | 38 | 38 | 38 | 38 |
| Weighted Avg Shares Out Dil | 38 | 38 | 38 | 38 |
| Supplemental Information | – | – | – | – |
| Interest Income | $56 | $22 | $8 | $20 |
| Interest Expense | $0 | $1 | $2 | $1 |
| Depreciation & Amortization | $31 | $35 | $26 | $24 |
| EBITDA | $38 | $55 | $165 | -$414 |
| % Margin | 6.1% | 9.7% | 29.4% | -75.4% |